News

The company intends to conduct the research work in cooperation with the University of British Columbia and the BC Cancer Agency. The data from preclinical trials showed anti-cancer

LabPartner is a provider of lab equipment, reagents, consumables and services for research and development. LabPartner delivers products and integrated services, with a focus on chemical distribution to

Roche‘s Boulder plant, engaged in the production of therapeutic peptide compounds, is equipped with large scale synthetic manufacturing technologies. The agreement allows ICIG to take over the technical

As per the terms of the agreement, GSK is responsible to pay up to EUR5.5m to MolMed in revenues for a term of two-year. Developed by the San

For the second quarter of 2011, the company has posted net loss of $51.51m, or $0.45 loss per diluted share, compared to $8.32m, or $0.08 loss per diluted

For the second quarter of 2011, the company has posted net loss of $17.3m, or $0.19 loss per diluted share, compared to $4.06m, or $0.05 loss per diluted

The companies’ decision was supported by the reevaluation of pramlintide/metreleptin program which had been in Phase 2 development as a twice-a-day injection formulation as a treatment for obesity.

Dabigatran etexilate is indicated as a preventive measure for stroke and systemic embolism in adult patients with non-valvular AF with one or more risk factors. The EC approval

Earlier, Palatin signed a research and licensing deal with AstraZeneca to develop, discover and commercialize compounds targeting melanocortin receptors to treat obesity, diabetes and related metabolic syndrome. The